Abstract:
:Fludarabine phosphate (2-F-ara-AMP) is an adenine nucleoside analogue that shows significant activity against chronic lymphocytic leukemia and indolent lymphoma. We assessed the cytotoxic interaction produced by the combination of the active metabolite of fludarabine phosphate, fludarabine (9-beta-D-arabinofuranosyl-2-fluoroadenine, 2-F-ara-A), and some commonly used antileukemic agents against human hairy cell leukemia cell line JOK-1, human chronic lymphocytic leukemia cell line SKW-3, and adult T cell leukemia cell lines ED-40810 (-) and SALT-3. The leukemia cells were exposed simultaneously to 2-F-ara-A and to the other agents for 4 days. Cell growth inhibition was determined using MTT reduction assay. The isobologram method of Steel and Peckham was used to evaluate the cytotoxic interaction. 2-F-ara-A and cytarabine showed synergistic effects in SKW-3 cells, additive and synergistic effects in JOK-1 and SALT-3 cells, and additive effects in ED-40810(-) cells. 2-F-ara-A and doxorubicin showed additive effects in SKW-3, ED-40810(-) and SALT-3 cell lines, and additive and synergistic effects in JOK-1 cells. 2-F-ara-A showed additive effects with etoposide, 4-hydroperoxy-cyclophosphamide, and hydroxyurea in all four cell lines. 2-F-ara-A showed antagonistic effects with methotrexate and vincristine in all four cell lines. Our findings suggest that the simultaneous administration of fludarabine phosphate with cytarabine, doxorubicin, etoposide, cyclophosphamide, or hydroxyurea would be advantageous for cytotoxic effects. Among these agents, cytarabine may be the best agent for the combination with fludarabine phosphate. The simultaneous administration of fludarabine phosphate with methotrexate or vincristine would have little cytotoxic effect, and this combination may be inappropriate. These findings may be useful in clinical trials of combination chemotherapy with fludarabine phosphate and these agents.
journal_name
Leukemiajournal_title
Leukemiaauthors
Kano Y,Akutsu M,Tsunoda S,Suzuki K,Ichikawa A,Furukawa Y,Bai L,Kon Kdoi
10.1038/sj.leu.2401684subject
Has Abstractpub_date
2000-03-01 00:00:00pages
379-88issue
3eissn
0887-6924issn
1476-5551journal_volume
14pub_type
杂志文章相关文献
LEUKEMIA文献大全abstract::Recent studies suggest that most cases of myelodysplastic syndrome (MDS) are clonally heterogeneous, with a founding clone and multiple subclones. It is not known whether specific gene mutations typically occur in founding clones or subclones. We screened a panel of 94 candidate genes in a cohort of 157 patients with ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2013.58
更新日期:2013-06-01 00:00:00
abstract::The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2011.71
更新日期:2011-07-01 00:00:00
abstract::Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemi...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403861
更新日期:2005-09-01 00:00:00
abstract::The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues, azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy for myelodysplastic syndromes and acute myeloid leukemia (AML), differ in structure and metabolism, suggesting that they may have differential mol...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2008.397
更新日期:2009-06-01 00:00:00
abstract::Malignant diseases induce immune responses against them which have variable success in controlling progression of disease. A variety of congenital and acquired disorders provide evidence in support of T cell or NK cell immune surveillance mechanisms in human hematological malignancies. Furthermore, clinical experience...
journal_title:Leukemia
pub_type: 杂志文章,评审
doi:10.1038/leu.2008.273
更新日期:2009-01-01 00:00:00
abstract::Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 2...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-020-0936-4
更新日期:2020-10-01 00:00:00
abstract::Early in mammalian development, the stem cell leukemia (SCL/TAL1) gene and its distinct 3' enhancer (SCL 3'En) specify bipotential progenitor cells that give rise to blood and endothelium, thus termed hemangioblasts. We have previously detected a minor population of SCL (+) cells in the postnatal kidney. Here, we demo...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404941
更新日期:2008-01-01 00:00:00
abstract::The c-kit proto-oncogene encodes a transmembrane receptor with a tyrosine kinase internal domain. C-kit has been mapped to the W locus in the mouse, and the gene encoding the ligand has been shown to be the product of the murine SI locus. Previous genetic studies have shown that the murine W and SI loci play important...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1991-06-01 00:00:00
abstract::Patients with acute myelogenous leukemia or myelodysplastic syndrome may respond to farnesyl transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients. FTIs prevent the attachment of a lipid farnesyl moiety to dependent proteins prior to their insertion into the plasma m...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403063
更新日期:2003-09-01 00:00:00
abstract::One-hundred, twenty-eight patients with Hodgkin's disease in remission or who had failed a mechlorethamine, vincristine, procarbazine and prednisone (MOPP), a doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) and/or lomustine, etoposide and prednimustine (CEP) regimens have been treated with a high-dose thera...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,多中心研究
doi:
更新日期:1991-01-01 00:00:00
abstract::Acute myeloid leukemia (AML) is a heterogeneous disease with multiple different cytogenetic and molecular aberrations contributing to leukemic transformation. We compared gene expression profiles of 4608 genes using cDNA-arrays from 20 AML patients (nine with -7/del7q and 11 with normal karyotype) with 23 CD34+ prepar...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2404093
更新日期:2006-03-01 00:00:00
abstract::In B-CLL IgV(H) genes mutational status is a major prognostic factor. Since sequencing of IgV(H) genes is not available in most laboratories, an easily performed surrogate assay is desirable. To identify the best surrogate assay, and to better discriminate prognostic subgroups we analyzed clinical and biological data ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402780
更新日期:2003-01-01 00:00:00
abstract::The t(14;18) chromosomal translocation occurs in most follicular non-Hodgkin's lymphomas and places the Bcl-2 gene on chromosome 18q21 into the immunoglobulin JH region on chromosome 14q32. This translocation can be exploited to detect clonal malignant cells bearing this genetic alteration. A polymerase chain reaction...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1993-01-01 00:00:00
abstract::Suppression of c-myc expression is observed during induced differentiation of several myeloid cell lines and it has been attributed to the cell growth arrest that accompanies terminal differentiation. To dissect the role of c-Myc in the proliferation-differentiation switch we have studied c-myc expression in K562 cell...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1993-11-01 00:00:00
abstract::Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells. To investigate whether chromosomal instability and/or DNA repair defects are involved in the development of MDS, we measured the micronucleus (MN) frequency in peripheral blood lymphocytes exposed to various doses of X-rays, using a cytok...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2402703
更新日期:2002-11-01 00:00:00
abstract::PRDM1/BLIMP-1, a master regulator of plasma-cell differentiation, is frequently inactivated in activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) patients. Little is known about its genetic aberrations and relevant clinical implications. A large series of patients with de novo DLBCL was effectively eval...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.243
更新日期:2017-03-01 00:00:00
abstract::The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2403943
更新日期:2005-11-01 00:00:00
abstract::Immunoglobulin (IG) gene repertoire restrictions strongly support antigen selection in the pathogenesis of chronic lymphocytic leukemia (CLL). Given the emerging multifarious interactions between CLL and bystander T cells, we sought to determine whether antigen(s) are also selecting T cells in CLL. We performed a larg...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2016.362
更新日期:2017-07-01 00:00:00
abstract::Patients with normal-karyotype acute myelogenous leukemia (NKAML) may have undetected genetic abnormalities that could affect prognosis. Screening for known AML-specific genetic abnormalities using the reverse transcription polymerase chain reaction (RT-PCR) may help in arriving at a more definitive prognosis. To test...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2401951
更新日期:2001-01-01 00:00:00
abstract::APL-associated hemostasis disorders result from at least two distinct mechanisms due to the release of procoagulant activities and plasminogen activators from the leukemic cells. These two mechanisms (thrombin activation and plasmin activation) may cleave the fibrinogen molecule, but their respective roles in low fibr...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-01-01 00:00:00
abstract::A population of CD133(+)Lin(-)CD45(-) very small embryonic/epiblast-like stem cells (VSELs) has been purified by multiparameter sorting from umbilical cord blood (UCB). To speed up isolation of these cells, we employed anti-CD133-conjugated paramagnetic beads followed by staining with Aldefluor to detect aldehyde dehy...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2011.73
更新日期:2011-08-01 00:00:00
abstract::In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxicity. At dose level 1 (DL1, 3 mg Ixa), 1/3 patients experienced grade ...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/s41375-018-0038-8
更新日期:2018-07-01 00:00:00
abstract::The wt1 gene is located on chromosome 11p13 and encodes a zinc finger motif-containing transcription factor involved in regulation of growth and differentiation. Its expression was shown during embryonic development in various tissues as well as in a few human malignancies including acute leukemias. Using RT-PCR, we f...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1995-06-01 00:00:00
abstract::We have previously identified sole +9, 13q- or 20q-, as 'favorable' and sole +8 or complex karyotype as 'unfavorable' cytogenetic abnormalities in primary myelofibrosis (PMF). In this study of 433 PMF patients, we describe additional sole abnormalities with favorable (chromosome 1 translocations/duplications) or unfav...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2010.234
更新日期:2011-01-01 00:00:00
abstract::Various clinical and laboratory observations suggest that the leukaemia cells in chronic myeloid leukaemia (CML) are potentially immunogenic. Whilst the ability of the leukaemia cells to elicit an anti-leukaemic immune response in the allogeneic setting is established, it remains unclear why such anti-leukaemic respon...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/sj.leu.2400858
更新日期:1997-12-01 00:00:00
abstract::Natural killer (NK) cells are cytotoxic lymphocytes that substantially contribute to the therapeutic benefit of antitumor antibodies like Rituximab, a crucial component in the treatment of B-cell malignancies. In chronic lymphocytic leukemia (CLL), the ability of NK cells to lyse the malignant cells and to mediate ant...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2015.50
更新日期:2015-08-01 00:00:00
abstract::The CD30+ anaplastic large cell lymphoma (ALCL) represents a new lymphoma entity thought to be related to Hodgkin'S disease (HD), but displaying also its own unique features. Cytogenetic studies of ALCL have demonstrated the presence of a (2;5)(p23;q35) translocation in a substantial number of these cases. Recently, t...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1996-01-01 00:00:00
abstract::Despite many years of meticulous immunophenotyping of childhood acute lymphoblastic leukaemia (ALL) cases the prognostic significance of some subtypes remains unclear. The Medical Research Council UKALLXI trial (1990-1996) in which uniform treatment has been given to 2090 children with ALL below the age of 18 years an...
journal_title:Leukemia
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1038/sj.leu.2401093
更新日期:1998-08-01 00:00:00
abstract::The molecular events which confer cellular resistance to cytotoxic drugs such as cytosine arabinoside (ara-C) are poorly understood. Nevertheless, in a proportion of patients with acute leukemia, such events will be responsible for the failure of therapy. Mutations which cause ara-C resistance in a chinese hamster ova...
journal_title:Leukemia
pub_type: 杂志文章
doi:
更新日期:1994-02-01 00:00:00
abstract::The FOXP1 (forkhead box P1) transcription factor is a marker of poor prognosis in diffuse large B-cell lymphoma (DLBCL). Here microarray analysis of FOXP1-silenced DLBCL cell lines identified differential regulation of immune response signatures and major histocompatibility complex class II (MHC II) genes as some of t...
journal_title:Leukemia
pub_type: 杂志文章
doi:10.1038/leu.2015.299
更新日期:2016-03-01 00:00:00